CJC-1295 isn't found on pharmacy shelves in Loil or most other cities — it's a research-grade peptide available through a dedicated online market. What this means for Loil researchers is that your location matters far less than your ability to assess COA data — and those quality checks are available to every researcher. A credible CJC-1295 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. Use this guide to evaluate CJC-1295 vendors rigorously — the framework here apply whether you are in Loil or anywhere else.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Loil studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
Before looking at individual vendors, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at minute levels. For Loil researchers evaluating new suppliers: a modest first purchase to test the product before placing larger orders is standard practice in the community. Keep lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order CJC-1295 — ships to Loil
COA-verified · International tracking · Research grade
CJC-1295 operates outside the framework of pharmaceutical oversight — researchers should understand that the risk characterisation for this compound is based on research literature rather than clinical trials. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; avoid repeatedly thawing and refreezing reconstituted peptide by preparing small aliquots before storage. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results reported in endotoxin units per mg or mL and verify they are within the acceptable range for your research context. The research literature on CJC-1295 should be read critically before designing any protocol — study methodologies, dosing, and endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
